LBF20406OX02: Difference between revisions

No edit summary
No edit summary
 
(15 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{Lipid/Header}}
{{Hierarchy|{{PAGENAME}}}}
{{Hierarchy|{{PAGENAME}}}}


{{Metabolite
{{Metabolite
|LipidBank=DFA8157
|LipidBank=DFA8157
|LipidMaps=-
|LipidMaps=LMFA03060019
|SysName=12-oxo-5Z,8Z,10E,14Z-eicosatetraenoic acid
|SysName=12-Oxo- (cis-5,cis-8,trans-10,cis-14) -eicosatetraenoic acid
|Common Name=&&12-oxo-5Z,8Z,10E,14Z-eicosatetraenoic acid&&
|Common Name=&&12-Oxo- (5Z,8Z,10E,14Z) -eicosatetraenoic acid&&
|UV Spectra=<FONT FACE="Symbol">l</FONT>max: 280nm <FONT FACE="Symbol">e</FONT>: 30,000
|UV Spectra= lambda max: 280nm  epsilon : 30,000
|Source=12-OxoETE is synthesized by human platelets and Aplaysia nervous tissue after incubation with arachidonic acid [[Reference:Falgueyret_JP:Leblanc_Y:Riendeau_D:,FEBS Lett.,1990,262,197|{{RelationTable/GetFirstAuthor|Reference:Falgueyret_JP:Leblanc_Y:Riendeau_D:,FEBS Lett.,1990,262,197}}]][[Reference:Fruteau_de_Laclos_B:Maclouf_J:Poubelle_P:Borgeat_P:,Prostaglandins,1987,33,315|{{RelationTable/GetFirstAuthor|Reference:Fruteau_de_Laclos_B:Maclouf_J:Poubelle_P:Borgeat_P:,Prostaglandins,1987,33,315}}]]. Microsomal fractions of various tissues will reduce 12-oxoETE to 12(S)-HETE or a mixture of 12(S)- and 12(R)-HETE [[Reference:Falgueyret_JP:Leblanc_Y:Riendeau_D:,FEBS Lett.,1990,262,197|{{RelationTable/GetFirstAuthor|Reference:Falgueyret_JP:Leblanc_Y:Riendeau_D:,FEBS Lett.,1990,262,197}}]][[Reference:Falgueyret_JP:Leblanc_Y:Rokach_J:Riendeau_D:,Biochem. Biophys. Res. Commun.,1988,156,1083|{{RelationTable/GetFirstAuthor|Reference:Falgueyret_JP:Leblanc_Y:Rokach_J:Riendeau_D:,Biochem. Biophys. Res. Commun.,1988,156,1083}}]].
|Chemical Synthesis=
|Metabolism=
|Symbol=12-OxoETE/12-KETE
|Biological Activity=12-OxoETE induces a rapid, dose related increase of cytoplasmic free calcium via a leukotriene B4 receptor or a common activation sequence [[Reference:Naccache_PH:Leblanc_Y:Rokach_J:Patrignani_P:Fruteau_de_Laclos_B:Borgeat_P:,Biochim. Biophys. Acta,1991,1133,102|{{RelationTable/GetFirstAuthor|Reference:Naccache_PH:Leblanc_Y:Rokach_J:Patrignani_P:Fruteau_de_Laclos_B:Borgeat_P:,Biochim. Biophys. Acta,1991,1133,102}}]].
}}
}}
{{Lipid/Footer}}

Latest revision as of 07:31, 21 October 2010

LipidBank Top
(トップ)
Fatty acid
(脂肪酸)
Glycerolipid
(グリセロ脂質)
Sphingolipid
(スフィンゴ脂質)
Journals
(雑誌一覧)
How to edit
(ページの書き方)


Upper classes: LB LBF



12-Oxo- (5Z,8Z,10E,14Z) -eicosatetraenoic acid
LBF20406OX02.png
Structural Information
12-Oxo- (cis-5,cis-8,trans-10,cis-14) -eicosatetraenoic acid
  • 12-Oxo- (5Z,8Z,10E,14Z) -eicosatetraenoic acid
12-OxoETE/12-KETE
Formula C20H30O3
Exact Mass 318.21949482599996
Average Mass 318.4504
SMILES C(CC=CCC(C=CC=CCC=CCCCC(O)=O)=O)CCC
Physicochemical Information
12-OxoETE is synthesized by human platelets and Aplaysia nervous tissue after incubation with arachidonic acid Falgueyret_JP et al. Fruteau_de_Laclos_B et al.. Microsomal fractions of various tissues will reduce 12-oxoETE to 12(S)-HETE or a mixture of 12(S)- and 12(R)-HETE Falgueyret_JP et al. Falgueyret_JP et al..
12-OxoETE induces a rapid, dose related increase of cytoplasmic free calcium via a leukotriene B4 receptor or a common activation sequence Naccache_PH et al..
Spectral Information
Mass Spectra
UV Spectra λ max: 280nm ε : 30,000
IR Spectra
NMR Spectra
Other Spectra
Chromatograms
Reported Metabolites, References
Biospecies ID Compound Name Reference Comment
n.a. LBF20406OX02 See above. Falgueyret_JP et al. 1990
n.a. LBF20406OX02 See above. Falgueyret_JP et al. 1988
n.a. LBF20406OX02 See above. Fruteau_de_Laclos_B et al. 1987
n.a. LBF20406OX02 See above. Naccache_PH et al. 1991